$ 211.92
Key Takeaways
Risk factor
Negligible price volatility
Profitability factor
Overvalued vs peers
About
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial...
Company Valuation
Based on key historical and expected multiples, the stock is overvalued relative to its peers. Specifically, the stock is fairly valued on P/E, overvalued on EV/EBITDA, r
Target Price
The average target price of ABBV is 202 and suggests 5% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation to decre
